Zoekresultaten - You searched for Cell therapy

539 results

Bone Therapeutics’ allogeneic cell therapy product, ALLOB, meets primary endpoints in Phase IIa

Read more

Bone Therapeutics receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform

Read more

FDA grants Fast Track Designation for Celyad’s ischemic heart failure therapy, C-Cure®

Read more

TiGenix confirms strategic focus on Cx601 and its adipose derived stem cell (eASC) platform

Read more

GST raises EUR 5 million to develop veterinary stem cell products

Read more

The first veterinary stem cell product recommended for approval in Europe becomes a reality

Read more

European scientists unite to track all cells in the human body

Read more

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

Read more

Bone Therapeutics Business Update for First Quarter 2017

Read more

Bone Therapeutics strengthens Board with the appointments of Steve Swinson and Damian Marron as Non-Executive Directors

Read more

Celyad obtains additional US patent for cancer treatment

Read more

Scientists give tumor-fighting cells a boost in battling bone marrow cancer

Read more

Bone Therapeutics Strengthens Board of Directors

Read more

Bone Therapeutics appoints Jean-Luc Vandebroek as Chief Financial Officer

Read more

Bone Therapeutics announces H1 results for 2017

Read more

Bone Therapeutics reports strong interim results from ALLOB® Phase IIA spinal fusion study

Read more

Bone Therapeutics and Asahi Kasei sign exclusive license agreement for PREOB® in Japan

Read more

Bone Therapeutics Business Update for Third Quarter 2017

Read more

Bone Therapeutics and Cellthera Pharm LLC announce intention to collaborate and Bone Therapeutics provides overview of its pipeline

Read more

Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae

Read more

Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease

Read more

Bone Therapeutics provides business outlook and announces its financial calendar for 2018

Read more

Bone Therapeutics completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB®

Read more

Bone Therapeutics strengthens Board with the appointment of Jean Stéphenne as Chairman

Read more

Bone Therapeutics Successfully Raises EUR 19.45 Million of Commitments in Convertible Bond Placement

Read more

Bone Therapeutics Reports Full Year 2017 Results

Read more

Bone Therapeutics Business Update for First Quarter 2018

Read more

Bone Therapeutics announces results of Annual General Meeting

Read more

Bone Therapeutics announces final results from Phase I/IIA ALLOB delayed-union fracture study

Read more

Bone Therapeutics to present at 26th Annual Meeting of the European Orthopaedic Research Society

Read more

Bone Therapeutics announces single intra-articular injection of viscosupplement JTA-004 delivered higher pain reduction than the reference in first study in knee osteoarthritis

Read more

Bone Therapeutics announces appointment of Linda Lebon as Chief Regulatory Officer

Read more

Bone Therapeutics announces conclusions from interim analysis of Phase III PREOB study in hip osteonecrosis

Read more

Bone Therapeutics announces 2019 business outlook and reports year-end 2018 cash position

Read more

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

Read more

PHD2 targeting overcomes breast cancer cell death upon glucose starvation

Read more

Biocartis Group NV: Biocartis and A*STAR's ETPL initiate development of breast cancer assay to guide therapy selection

Read more

Promethera Biosciences and Shibuya Announce Strategic Collaboration to Establish Breakthrough Cell Therapy Manufacturing Platform

Read more

Promethera Biosciences Presents Novel Data on HepaStem’s Ability to Reduce Key Disease Parameters in Advanced Stage NASH in vivo Model

Read more

VIB: Artificial intelligence sheds new light on cell developmental dynamics

Read more

Detailed brain map uncovers hidden immune cells that may be involved in neurodegenerative disorders

Read more

Promethera Biosciences Announces First-Dosing in Phase 2a Clinical Study Evaluating World’s First Liver Stem Cell Therapy in Late-Stage NASH Patients

Read more

Preventing cell death as novel therapeutic strategy for rheumatoid arthritis

Read more

VIB: Salty diet reduces tumor growth by tackling immune cells

Read more

Specialized blood vessels enhance tumor-fighting immunotherapy

Read more

Bone Therapeutics completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB®

Read more

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Read more

Celyad publishes additional pre-clinical data in support of THINK trial

Read more

Celyad announces initiation of the SHRINK trial

Read more

TiGenix obtains commercial production license for expanded manufacturing facility

Read more

Bone Therapeutics announces all patients meet primary endpoint in ALLOB® Phase I/IIA delayed-union study interim analysis

Read more

TiGenix to participate and present at key investor and business development meetings

Read more

TiGenix granted Orphan Drug Designation from the U.S. FDA for Cx601

Read more

TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure

Read more

TiGenix strengthens European IP protection around lead development program Cx601

Read more

Celyad Successfully Doses First Colorectal Cancer Patient with CYAD-01 Following Preconditioning Chemotherapy

Read more

Celyad’s 2019 R&D Day Highlights shRNA Platform and Pipeline of Next-generation NKG2D-based and Off-the-Shelf Non-gene Edited CAR-T Candidates

Read more

Bone Therapeutics successfully raises EUR 8.5 million

Read more

Promethera Biosciences Presents Preclinical Data on Novel H2Stem Cell Therapy at EASL International Liver Congress

Read more

Esperite N.V. with CryoSave contributes to treating a 9 year old child with thalassema major in Switzerland

Read more

Celyad Announces First Quarter 2017 Business Update

Read more

Celyad announces new agreements with Celdara medical and Dartmouth College

Read more

Celyad Reports First Half 2017 Financial Results and Operational Progress

Read more

Newly described process in Parkinson’s protein as a potential new therapy route

Read more

Celyad Announces Third Quarter 2017 Business Update

Read more

Promethera Biosciences Provides Update on Executive Management Team

Read more

eTheRNA completes enrolment of low dose cohort for Phase 1b study of TriMix mRNA-based cancer specific immunotherapy (ECI-006) in melanoma

Read more

Promethera Biosciences Acquires Baliopharm AG to Strengthen its Therapeutic Strategy in NASH With a Unique Tumor Necrosis Factor Receptor 1 (TNF-R1) Antibody Drug Candidates

Read more

Promethera Biosciences Establishes Branch Office in Tokyo

Read more

TiGenix announces a change in its Board of Directors and its Management Team

Read more

Promethera Biosciences Appoints Mutsuki Takano as General Manager of its Branch Office in Tokyo

Read more

Promethera Biosciences Announces Investment by ITOCHU Corporation and a Broad Strategic Collaboration to Access the Asian Markets

Read more

Biocartis and Kite Sign Agreement for Development of Assays supporting Kite's Therapies

Read more

eTheRNA: Safety and immune stimulation data from an intranodal delivery of TriMix mRNA, in the adjuvant melanoma study E011-MEL

Read more

TiGenix reports 2016 full year results

Read more

Celyad initiates second dose escalation in THINK trial in first US patient

Read more

TiGenix Cx601 positive long-term results to be presented at Digestive Disease Week

Read more

TiGenix to present at the Crohn's and Colitis Foundation's Novel Technologies in Inflammatory Bowel Disease workshop in New York

Read more

VIB: Researchers identify nutrient metabolism that drives breast tumor metastasis

Read more

Towards the Future: Synergizing Efforts for the Next Generation of Cell Therapeutics

Read more

Swissmedic has accepted for review the file on Cx601 for the treatment of Crohn's disease patients

Read more

Bone Therapeutics Notice of Half Year 2017 Results

Read more

Bone Therapeutics to participate in upcoming key investor and partnering conferences in Q4 2017

Read more

Bone Therapeutics Launches Equity Placement

Read more

Bone Therapeutics Provides Update on Equity Placement

Read more

Bone Therapeutics announces private placement of convertible bonds

Read more

Bone Therapeutics Notice of Full Year 2017 Results

Read more

Bone Therapeutics Strengthens Board with the Appointment of Claudia D’Augusta as Non-Executive Director

Read more

Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed/Refractory AML Patient

Read more

Bone Therapeutics Information on the total number of voting rights and shares

Read more

Bone Therapeutics: preliminary documents for the Annual Ordinary and the Extraordinary General Shareholder Meeting

Read more

Bone Therapeutics: Information on the total number of voting rights and shares

Read more

Dr. Margo Roberts joins Celyad’s Board of Directors and Scientific Committee

Read more

Bone Therapeutics Notice of Half Year 2018 Results

Read more

Celyad Appoints Carri Duncan as Vice-President Corporate Development & Communications

Read more

Information on the total number of voting rights and shares

Read more

Bone Therapeutics Notice of Full Year 2018 Results

Read more

Science for Health 2019

Read more

VIB: Towards a safer treatment for leukemia

Read more

Celyad Announces Strategic Updates to the Autologous r/r AML and MDS Program

Read more

VIB: Waking up sleeping bacteria to fight infections

Read more

MDxHealth Epigenetic Biomarkers Identify Men at Increased Risk of Prostate Cancer Recurrence

Read more

Esperite (ESP), The Cell Factory demonstrate anti-inflammatory mode of action of CF-MEV-117 extracellular vesicle drug candidate for Epilepsy

Read more

TiGenix announces final equity payment for cardiac platform acquisition

Read more

eTheRNA immunotherapies advances In-Vivo mRNA Cancer Immunotherapy into first Oncology Clinical Studies

Read more

Promethera Announces Review Acceptance of Heparesc New Drug Submission for Neonatal Onset Urea Cycle Disorders by Health Canada

Read more

Delphi Genetics receives GMP accreditation for plasmid DNA bioproduction

Read more

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Read more

Mithra Announces Completion of Recruitment in Donesta® Phase II Study

Read more

TiGenix announces approval of trade name for lead development candidate Cx601 in Europe

Read more

TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting

Read more

argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting

Read more

Takeda announces its intention to acquire TiGenix

Read more

TiGenix announces publication in Gastroenterology of 52-week results of the Phase III ADMIRE-CD trial of Cx601 (darvadstrocel) in the treatment of complex perianal fistulas in Crohn’s disease

Read more

MDxHealth (R): Develops Blood Test to Guide Precision-Treatment of Castration-Resistant Prostate Cancer Patients

Read more

Promethera Biosciences Announces Updates to its Board of Directors

Read more

Promethera Biosciences Raised Additional EUR 9.3 Million to Advance a Broad Product Pipeline in Severe Liver Diseases

Read more

Mithra announces further positive phase IBB Donesta® efficacy and safety data

Read more

V-Bio Ventures participates in 22.5 million euros series B financing round of HORAMA

Read more

Mithra: full Estetrol (E4) program update provided at scientific advisory board meetings

Read more

argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110)

Read more

First patient recruited in collaborative Phase 1 study to evaluate TriMix in breast cancer patients

Read more

Sequana Medical announces presentation of positive DSR clinical proof-of-concept data demonstrating potential in volume overload due to heart failure

Read more

eTheRNA: Linking clinical cure of metastatic melanoma with immune responses in the TriMix DC-MEL IPI study.

Read more

Scientists expose protein responsible for allergic diseases

Read more

Biocartis Group NV: Biocartis Q1 2017 Business Update

Read more

Tau prevents synaptic transmission at early stage of neurodegeneration

Read more

Cell Death and Immunity in Disease: from molecules to translational medicine

Read more

TiGenix Launches Global Phase III Trial for Cx601

Read more

TiGenix opens US headquarters in Cambridge, MA

Read more

Novel perspectives on anti-amyloid treatment for the prevention of Alzheimer’s disease

Read more

ConfirmMDx Featured in OncologyLive Magazine

Read more

Scientists unravel role of glutamine synthetase in the spread of cancer

Read more

TiGenix strengthens US operations with senior appointments

Read more

Camel-IDS appoints Ruth Devenyns as Chief Executive Officer

Read more

Scientists pinpoint surprising origin of melanoma

Read more

Galapagos initiates Phase 1 study with novel CF corrector GLPG3221

Read more

Galapagos - Update on progress in cystic fibrosis programs

Read more

Scientists discover how treating eczema could also alleviate asthma

Read more

HDAC6 inhibitors protect against neuronal damage and have therapeutic potential in both neurology and oncology

Read more

Imec Introduces CMOS Chip With 16,384 Micro-electrodes and 1,024 Channels for Multimodal Cell Interfacing

Read more

Counteracting the effects of TNF receptor-1 has therapeutic potential in Alzheimer’s disease

Read more

Biocartis announces 2017 results and 2018 outlook

Read more

flanders.bio - Roche Diagnostics Partner Day 2018: ’Towards high-quality Cell Therapy’

Read more

Galapagos reports initiation of FALCON clinical trial in cystic fibrosis

Read more

Biocartis Q1 2018 business update

Read more

Imec Presents Novel Organ-on-Chip Platform for Drug Screening

Read more

Celyad Reports First Half 2018 Financial Results and Operational Progress

Read more

Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response

Read more

argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia

Read more

argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia

Read more

Celyad Outlines Key 2019 Priorities Including the Acceleration of the CYAD-01 Program in r/r AML and MDS

Read more

Celyad Appoints Anne Moore as Vice President Corporate Strategy

Read more

Structure of the molecular machine that links carbohydrate and lipid metabolism

Read more

Do ‘microglia’ hold the key to stop Alzheimer’s disease?

Read more

New social, ethical & economic impact studies and activities developed by Sanquin

Read more

5 Flemish universities reveal innovative state-of-the-art biotech research at knowledge for growth 2019

Read more

VIB: Using ketone bodies in the fight against lymphedema

Read more

Kiadis Pharma’s Pediatric Investigation Plan for ATIR101™ accepted by the European Medicines Agency’s Pediatric Committee

Read more

Kiadis Pharma announces Annual Results for the year ended December 31, 2016

Read more

TiGenix to participate in key investor conferences in April 2017

Read more

Argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients

Read more

Celyad to Present at the Deutsche Bank 42nd Annual Health Care Conference

Read more

MDxHealth Trading Update: January to April 2017

Read more

TiGenix to present at Bank of America Merrill Lynch 2017 Healthcare Conference in Las Vegas

Read more

Multiplicom launches complete CE-IVD marked solution in Europe for all BRCA testing needs

Read more

ThromboGenics NV to present THR-317 Pre-clinical Research Findings

Read more

Mithra Obtains Marketing Authorization for Tibelia® in France

Read more

TiGenix to present at the Jefferies 2017 Global Healthcare Conference in New York

Read more

TiGenix Partners with U.S. and European Patient Advocacy Groups Focused on Crohn’s Disease and Ulcerative Colitis

Read more

MDxHealth and Queensland University of Technology Collaborate on Oral Cancer Liquid Biopsy Test

Read more

argenx presents full data from ARGX-111 Phase Ib study in patients with advanced cancers over-expressing the MET protein

Read more

Ablynx receives fast track designation from the FDA for Caplacizumab for the treatment of acquired TTP

Read more

ThromboGenics Business Update - H1 2017

Read more

argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis

Read more

eTheRNA immunotherapies awarded €1 million grant from Flanders Innovation & Entrepreneurship

Read more

Promethera Biosciences to Present at Several International Partnering and Scientific Conferences this Fall

Read more

Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients

Read more

TiGenix to present positive 52-week Phase III results of Cx601 at World Congress of Gastroenterology at ACG 2017 meeting

Read more

ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR

Read more

ThromboGenics Business Update - Q3 2017

Read more

TiGenix announces partial conversion of bonds

Read more

iTeos Therapeutics to Present New Data at Upcoming 2017 SITC Annual Meeting

Read more

Mithra Announces 36-month Shelf Life Extension for Tibelia®

Read more

Metabolism in Cancer and Stromal Cells (2nd edition)

Read more

Mithra Announces Last Subject Completes Donesta® Phase II Study

Read more

VLAIO kent QbD subsidie toe voor innovatie in celtherapie procesontwikkeling

Read more

argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe

Read more

ActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib/IIa Trial with AG019 for the Treatment of Early Onset Type 1 Diabetes

Read more

Promethera Biosciences to Present New NASH Data at Two International Scientific and Partnering Conferences in April

Read more

Do you have to become officially a BIOBANK under the new Belgian law?

Read more

Mithra launches capital increase by means of a private placement via an accelerated bookbuild offering

Read more

Takeda and TiGenix Announce Results of First Acceptance Period for the Voluntary and Conditional Public Takeover Bid of TiGenix and Commencement of Second Acceptance Period

Read more

Mithra Announces Presentation of Donesta® Results at the International Menopause Society’s 16th World Congress

Read more

argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation

Read more

argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris

Read more

Mithra and Mediner sign LSA for Tibelia® in Hungary

Read more

Mithra announces positive top-line results of estelle® phase III oral contraceptive study in eu/russia

Read more

Mithra signs exclusive license and supply agreement for commercialization of Tibelia® in Taiwan

Read more

Mithra Announces 2018 Half Year Results

Read more

Presentation of Donesta® PHIIB results at the 2018 annual meeting of the North American menopause society

Read more

Mithra: 2018 update and 2019 outlook given at the cphi conference

Read more

Mithra signs exclusive license and supply agreement with Adcock Ingram for commercialization of Estelle® in Southern Africa

Read more

argenx announces new cusatuzumab (ARGX-110) AML data in abstracts

Read more

Type 2 Immunity in Homeostasis and Disease

Read more

The Brain Mosaic: Cellular heterogeneity in the CNS (2nd edition)

Read more

Blockbuster Potential in Perimenopause with new E4 Candidate and Acceleration of Donesta Phase III Program

Read more

Mithra Announces Positive Top-line Results of Estelle® Phase III Oral Contraceptive Study in U.S/Canada

Read more

eTheRNA immunotherapies completes patient enrolment for Phase Ib-study in adjuvant melanoma

Read more

Mithra Signs License and Supply Agreement for Commercialization of Tibelia® in Chile

Read more

Advanced & breakthrough therapies: from idea to patient

Read more

Promethera Biosciences Completes €39.7 Million ($44.4 Million) Series D Financing

Read more

Mithra Signs LSA for Commercialization of Myring™ in Germany, the biggest market in Europe

Read more

Genkyotex Announces FDA Approval of Phase 2 Investigator-Initiated Trial with GKT831 in IPF

Read more

flanders.bio provides you with insights in the vibrant life sciences sector

Read more

argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia

Read more

Symposium on Sepsis

Read more

Phase Transitions in Biology and Disease

Read more

argenx receives first preclinical milestone payment in AbbVie collaboration

Read more

Biogazelle offers unique mRNA sequencing on plasma

Read more

Galapagos reports first quarter 2017 results

Read more

Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI

Read more

VIB: A new unexpected key player in melanoma development identified

Read more

MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics

Read more

FairJourney Biologics announces an innovative technology to discover antibody molecules in full therapeutic format

Read more

ABLYNX REPORTS FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2017 AND A YEAR-TO-DATE BUSINESS UPDATE

Read more

Esperite (ESP): Patent granted in China for treatment of acute and chronic inflammatory and autoimmune diseases with EVs technology

Read more

ThromboGenics Business Update - Q1 2017

Read more

Galapagos NV: Seven abstracts on filgotinib accepted by EULAR 2017

Read more

Galapagos to hold Annual R&D Update 2017 on 20 June

Read more

Genohm releases new SLims Workflow for NIPT

Read more

Biocartis Group NV: MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer

Read more

Biocartis launches CE-marked IVD test for lung cancer

Read more

Galapagos' R&D Update 2017: rapidly advancing our product candidates

Read more

Researchers gain new insights into the formation of non-pathological amyloids

Read more

Mithra Launches a Capital Increase by Means of a Private Placement via an Accelerated Bookbuild Offering

Read more

TiGenix to present at the 7th TERMIS-EU Conference in Davos, Switzerland

Read more

Daily Newsflash- 29/06/17

Read more

BioInvent and ThromboGenics Amending Long-Standing Monoclonal Antibody Development Agreement

Read more

GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial

Read more

Navigation and spatial memory: new brain region identified to be involved

Read more

Ablynx announces 2017 half year results and year-to-date business update

Read more

Genohm announced today the signing of several new clients

Read more

Biocartis announces H1 2017 results

Read more

Advipro (Lille+Willebroek) scoort met Europese scoop voor farmasector en investeert in uniek trainingscenter met operationele cleanroom

Read more

Imec Leverages the Power of Silicon Fabrication to Create Innovative Neural Probe Demonstrator with Unprecedented Electrode Density

Read more

International recognition for Dirk Inzé

Read more

Consistent safety findings and durable activity with filgotinib treatment of rheumatoid arthritis patients up to week 84 in DARWIN 3 study

Read more

Imec Designs and Fabricates World-First Miniature Neural Probe for Simultaneous Recording of Multiple Brain Regions at Neuronal Resolution

Read more

Biocartis Group NV: BIOCARTIS Q3 2017 BUSINESS UPDATE

Read more

Ablynx announces results for the first nine months of 2017 and a year-to-date business update

Read more

Count your blessings: Quantitative Microbiome Profiling

Read more

ALBATROSS with GLPG2222 shows positive clinical results in CF patients

Read more

Scientists shed light on a tumor-suppressive protein In metastases

Read more

New start-up Aelin Therapeutics secures 27M Euros to pioneer the development of a novel drug modality

Read more

Galapagos exercises co-promotion option for filgotinib with collaboration partner Gilead Sciences in eight European countries

Read more

Will 2018 be the year of biotech M&A? - An analysis by KBC Securities

Read more

Sanofi to acquire Ablynx for €3.9 Billion

Read more

Closing in on Tau: Researchers identify a new synaptic player in early stages of neurodegeneration

Read more

Acacia Pharma announces its intention to launch an initial global offering and to list its shares on Euronext Brussels

Read more

Ablynx announces 2017 full year results

Read more

Scientists discover how to increase both sugar yield and biomass production in the model plant Arabidopsis

Read more

Convert Pharmaceuticals secures EUR 13,6 million to develop anti-cancer drugs

Read more

Trapping multidrug-resistant bacteria in molecular glue

Read more

argenx reports fourth quarter business update and full year 2017 financial results

Read more

CMAST supports Rejuvenate Biomed in their search for ways to impact the ageing process

Read more

VIB Plant-derived volatiles may serve as future antifungals

Read more

Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018

Read more

Networking - 14/06/2018

Read more

Mithra Announces Positive Donesta® Phase IIb Study Achieving Primary Objective and Confirming Promising Safety Profile

Read more

Imec demonstrates direct optical reading of single-molecule DNA bases in modified nanopores

Read more

CoBioRes receives a € 1.7M grant from VLAIO to support its tetrapeptide prodrug research for treatment of Triple Negative Breast Cancer

Read more

Biocartis Group NV: Study Demonstrates Ability of Idylla(TM) EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests

Read more

VIB: New genes found only in humans shed light on unique features of brain development

Read more

SCK•CEN seminar to discover the latest innovations in nuclear medicine

Read more

Galapagos: Topline results of PELICAN trial and update on triple combo development plans

Read more

TiGenix: Transparency Information

Read more

Galapagos announces design for PINTA Phase 2 trial with GLPG1205 in IPF

Read more

Workshop: Meet the Biobank Experts

Read more

Bioprocessing in the future: Single-Use and Continuous

Read more

Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1)

Read more

Oxurion NV Business Update - Q3 2018

Read more

Biocartis Group NV: Studies on Idylla(TM) MSI and RAS liquid biopsy tests to be presented at ESMO congress

Read more

Galapagos: Positive trial results with filgotinib in psoriatic arthritis and ankylosing spondylitis both published in the lancet

Read more

Galapagos and AbbVie restructure CF collaboration

Read more

argenx reports third quarter 2018 financial results and provides business update

Read more

Imec Releases Neuropixels Neural Probe to the Global Neuroscience Community

Read more

Life on chip: the road from idea to reality

Read more

Biocartis and AstraZeneca Enter Into Agreement Aimed at Faster Lung Cancer Biomarker Results

Read more

Course: Radiation-induced effects with particular emphasis on genetics, development, teratology, cognition as well as space-related health issues

Read more

Call for project ideas on Personalised Medicine

Read more

Naar een coöperatief model voor de Life Sciences: Antleron wijst de weg

Read more

Oxurion NV Business Update - FY 2018

Read more

The European Bank for induced pluripotent Stem Cells launches a second project phase

Read more

Plant immunity cut to size

Read more

5 VIB researchers receive an exceptional ERC Advanced grant

Read more

VIB: Edible antibodies to treat and prevent gastrointestinal disorders

Read more

Oxurion NV announces full enrollment of its Phase 2 trial for treatment of DME, ahead of schedule

Read more

VIB: From spinal cord injury to recovery

Read more

flanders.health Personalised Medicine event

Read more

Registration open for the flanders.health partnering event on Personalised Medicine (28/05)

Read more

Invitation: Science for health (11/09/2019, Square Brussels)

Read more

flanders.health Personalised Medicine event (28/11, Leuven)

Read more

ViroVet and Pirbright join forces to develop African swine fever antivirals

Read more

Winnaar van de Dr. Paul Janssen Award voor Biomedisch Onderzoek bekend

Read more

VIB scientist Wout Boerjan elected as EMBO Member

Read more

VIB-KU Leuven: Duvel Moortgat opens scientific pilot brewery and presents BSSH Awards to Sir Paul Nurse, 2001 Nobel Laureate

Read more

Single-Use Event 2018: Bioprocessing in the future: Single Use and Continuous

Read more

Reminder: Science for health (11/09/2019, Square Brussels)

Read more

FDA approves new cancer drug associated with KU Leuven discovery

Read more

Gilead and Galapagos enter into transformative research and development collaboration

Read more

VIB: Stripping down bacterial armor: a new way to fight anthrax

Read more

De 2019 Dr. Paul Janssen Award voor Biomedisch Onderzoek voor F.-Ulrich Hartl en Arthur Horwich

Read more

MyCartis and XVIVO Perfusion AB engage to develop a fast diagnostic test to assess the quality of donated organs before transplantation

Read more

Kiadis Pharma announces positive regulatory update on ATIR101™ and ATIR201™

Read more

MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Read more

New Study Shows MDxHealth's SelectMDx Test is Cost-Effective for Biopsy Selection

Read more

13th International Conference on Renewable Resources & Biorefineries

Read more

ThromboGenics Achieves Important Milestone in the Development of THR-149

Read more

MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx

Read more

ABLYNX COMPLETES PATIENT RECRUITMENT IN ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF aTTP

Read more

ThromboGenics NV : New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore

Read more

Nieuws van de dag - 3/05/2017

Read more

argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis

Read more

Nieuws van de dag- 5/05/2017

Read more

Nieuws van de dag- 12/05/2017

Read more

Mithra to Initiate PK Study for Estelle®

Read more

ConfirmMDx Improves Prostate Cancer Diagnosis in African American Men

Read more

SelectMDx for Prostate Cancer Guides Patient Selection for mpMRI

Read more

MDxHealth Shareholder Transparency Notification

Read more

Overnight skin care

Read more

Mithra & Gynial sign commercialization agreement for MyringTM in Austria

Read more

Mithra Receives GMP Approval for Myring™ Production

Read more

MDxHealth: Annual General Shareholders' Meeting

Read more

Nieuws van de dag- 01/06/2017

Read more

Mithra Signs Exclusive Agreement for Tibelia® in Canada

Read more

ThromboGenics to Present the Industry Pipeline of DME Treatments

Read more

Mithra Receives Orphan Drug Designation from EMA for E4 in Neonatal Encephalopathy

Read more

Kiadis Pharma raises €5 million in private placement with institutional investors

Read more

Ablynx to present additional data for its anti-IL-6R nanobody, vobarilizumab, at the annual European Congress of Rheumatology

Read more

argenx presents update on Phase I data from ARGX-110 expansion study in patients with cutaneous T-cell lymphomas

Read more

REGMED Europe

Read more

Internationalisation

Read more

Symposium on Liquid Biopsies & Cancer

Read more

Mithra Successfully Raises €26.1 Million

Read more

Daily Newsflash- 23/06/17

Read more

Ablynx initiates a single and multiple dose phase I study of caplacizumab in healthy Japanese subjects

Read more

MDxHealth Presents Three SelectMDx Studies at 5th Global Congress on Prostate Cancer

Read more

Mithra Signs Exclusive License and Supply Agreement with Fuji Pharma for Donesta® in Japan and Asean

Read more

Lack of Knowledge on Clinical Advances Achieved by New Generation of Biomarker Tests for Prostate Cancer

Read more

Daily Newsflash- 5/07/2017

Read more

MDxHealth Launches AssureMDx for Bladder Cancer Liquid Biopsy Test

Read more

Mithra Strengthens E4 Patent Position in Australian Market

Read more

SelectMDx to be Distributed Across Middle East by IPS Genomix

Read more

Mithra Submits Myring™ for European Marketing Approval

Read more

MVZ Dr. Stein & Kollegen First German Medical Laboratory to Offer the SelectMDx for Prostate Cancer Test

Read more

MDxHealth to Participate in Canaccord Genuity Growth Conference

Read more

MDxHealth Appoints Seasoned EVP to Lead Sales Force Expansion

Read more

MDxHealth Announces Service Agreement with Kaiser Southern California Permanente Medical Group

Read more

Mithra: Recruitment Completed in Estelle® Population PK Substudy

Read more

ConfirmMDx Study Provides Further Validation of Epigenetic Risk Profile

Read more

MDxHealth Notice of January-June 2017 Financial Results

Read more

New ThromboGenics' Ocriplasmin Clinical and Health Economic Data Presented at ASRS 2017 Annual Scientific Meeting in Boston

Read more

Mithra Announces First Subject Completes Estelle® Phase III Study

Read more

MDxHealth Announces First Half 2017 Financial Results

Read more

MDxHealth Prepares for Growth with Executive Team Expansion

Read more

SelectMDx Outperforms PCA3 Stratifying Men for mpMRI

Read more

ThromboGenics Regains Global Rights to JETREA® (ocriplasmin)

Read more

Daily Newsflash- 18/09/2017

Read more

argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia

Read more

Mithra announces 2017 half year results

Read more

argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris

Read more

ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting

Read more

ThromboGenics Successfully Introduces New 'Already-Diluted' Formulation of JETREA® (ocriplasmin) in the US

Read more

Ablynx announces positive topline results from the Phase III Hercules Study of Caplacizumab for the treatment of acquired TTP

Read more

MDxHealth Opens New Service and Research Laboratory in The Netherlands

Read more

Mithra’s Marketing Authorization Application for Tibelia® Accepted by Health Canada

Read more

Daily Newsflash- 13/10/2017

Read more

Ablynx establishes subsidiary in the USA and appoints a general manager

Read more

argenx launches Phase I trial with subcutaneous formulation of ARGX-113

Read more

MDxhealth Enters into Distribution Agreement with Unilabs for SelectMDx for Prostate Cancer

Read more

Mithra Completes Recruitment for Estelle® Phase III Study in US and Canada

Read more

Mithra Announces Launch of Warrant Exercise Period

Read more

MDxHealth Nine Month Trading Update

Read more

ThromboGenics Strengthens Leadership Team

Read more

Daily Newsflash- 13/11/2017

Read more

Life Sciences Baltics 2018

Read more

Personalised Medicine - van lab naar patiënt

Read more

Mithra Announces Positive Outcome of Myring™ Commercial Batch Bioequivalence Study

Read more

MDxhealth teams up with Pharmaceutical Company Ferrer for distribution of its Prostate Cancer test SelectMDx in Spain

Read more

Ablynx - Results from the Phase III Hercules Study of Caplacizumab for the treatment of acquired TTP selected for presentation in the late-breaking abstracts session at the 2017 ASH annual meeting

Read more

Publication of a Transparency Notification Received by Mithra Pharmaceuticals sa/nv

Read more

JPMorgan Chase & Co notifies 3.12% shareholding in TiGenix

Read more

Mithra Confirms Conversion of Subscription Rights

Read more

Mithra Provides Update on Estelle® and Donesta® Studies

Read more

Mithra Announces Valorization of French Subsidiary

Read more

Ablynx to host webcast about Phase III Hercules Study

Read more

Daily Newsflash - 8/12/2017

Read more

argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

Read more

Ablynx reports additional clinically important benefits of Caplacizumab from its Phase III Hercules Study in acquired TTP

Read more

reMYND enters into license agreement with Novo Nordisk

Read more

Mithra Announces Injectables Agreement with GSP

Read more

Confo Therapeutics enters into drug discovery collaboration with Roche

Read more

Ablynx announces positive data from its Japanese ethno-bridging study of Caplacizumab

Read more

Mithra and Adamed Sign Commercialization Agreement for MyringTM in the Czech Republic

Read more

MDxHealth Announces Lowering of 2017 Guidance

Read more

TiGenix Transparency notification pursuant to Article 14 of the Law of May 2, 2007

Read more

Rewind Therapeutics secures 15.2 M EURO to develop novel remyelination therapies

Read more

iTeos Therapeutics Regains Worldwide Rights to Clinical-Stage IDO1 Inhibitor

Read more

12th Conference on Protein Stabilization (ProtStab 2018)

Read more

TiGenix - Transparency Information

Read more

TiGenix - Transparency notifications pursuant to Article 14 of the Law of May 2, 2007

Read more

Mithra announces very promising hemostasis results for Estelle®

Read more

MDxHealth Notice of Financial Year 2017 Results

Read more

Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego

Read more

MDxHealth financial results

Read more

MDxHealth contract SelectMDx with Roman Hospital

Read more

Ablynx commences dosing in its Phase II Study of ALX-0171 in hospitalised Japanese infants with a RSV infection

Read more

Mithra Reports 2017 Annual Results

Read more

Mithra presents positive hemostasis results at ISGE conference

Read more

Argenx awarded €2.5 million VLAIO grant to identify novel therapeutic antibodies

Read more

MITHRA and ALVOGEN sign LSA for vaginal contraception ring in Russia

Read more

MDxHealth (R): SelectMDx Liquid Biopsy Test for Prostate Cancer included in the 2018 European Association Urology Guidelines

Read more

Argenx announces expansion of its pipeline with addition of complement-targeted ARGX-117 for treatment of severe autoimmune diseases

Read more

Mithra Announces Completion of Estelle® Cycles Required in Phase III Contraception Studies

Read more

TiGenix en Takeda kondigen aan dat Alofisel® (darvadstrocel) de goedkeuring krijgt voor de behandeling in Europa van complexe perianale fistels bij de ziekte van Crohn

Read more

Mithra applies for additional estelle® patent based on positive hemostasis data

Read more

MDxHealth's New Share Capital Amount and New Number of Shares

Read more

MDxHealth Shareholder Transparency Declaration

Read more

argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting

Read more

TiGenix Transparency notifications pursuant to Article 14 of the Law of May 2, 2007

Read more

MDxHealth Shareholder Transparency Declaration

Read more

Grünenthal en KU Leuven bundelen de krachten om een nieuwe niet-opioïde pijnstiller te ontwikkelen

Read more

Mithra signs principle agreement for commercialization of Estelle® in canada

Read more

Mithra releases 2017 Annual Report and invitation to its Ordinary General Shareholders' Meeting

Read more

MDxHealth (R): SelectMDx Included in Dutch DRG Reimbursement System

Read more

MDxHealth Provides First Quarter 2018 Business Update

Read more

argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting

Read more

MDxHealth Announces Positive Clinical Updates for ConfirmMDx

Read more

MDxHealth releases 2017 Annual Report

Read more

Ablynx completes patient recruitment in the Phase IIb Respire Study of its inhaled anti-RSV Nanobody ALX-0171

Read more

Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients

Read more

Information regarding Belgian biobank law and international standards

Read more

Mithra announces injectable contract with Midas Pharma

Read more

Daily newsflash - 16/05/2018

Read more

MDxHealth (R): Presentation of New Data on MDxHealth's Prostate and Bladder Cancer Products at AUA 2018 Annual Meeting

Read more

Update on mithra and mayne pharma’s vaginal contraceptive ring opportunity

Read more

Mithra successfully raises eur 77.5 million

Read more

MDxHealth Annual General Shareholders' Meeting

Read more

Mithra signs binding heads of terms for commercialization of Estelle® in South Korea with women's health specialist Hyundai Pharm

Read more

Mithra: information on the total number of voting rights

Read more

MDxHealth launch agreement with Philips for prognostic prostate cancer biomarker

Read more

argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis

Read more

Daily newsflash - 07/06/2018

Read more

Daily Newsflash - 14/06/2018

Read more

MDxHealth's SelectMDx Test Successfully Stratifies Men

Read more

Mithra: Publication of a Transparency Notification Received from François Fornieri

Read more

Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix

Read more

MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner

Read more

Mithra Obtains First Marketing Authorization for Myring™ in Europe

Read more

MDxHealth (R): Medicare Establishes Final Positive Local Coverage Determination for Use of ConfirmMDx for Prostate Cancer

Read more

argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Journal of Clinical Investigation

Read more

Mithra announces belux agreement with ceres pharma worth over eur 40 million

Read more

MDxHealth: SelectMDx Study Demonstrates Cost-effectiveness in US Healthcare System

Read more

The FAMPH has published the Compendium on Biobank legislation

Read more

MDxHealth (R): MDxHealth Shareholder Transparency Declaration

Read more

Rejuvenate Biomed awarded €460,000 grant from VLAIO to accelerate drug development for healthy aging

Read more

Press Release - Life Sciences & Biotechnology - 10/08/2018

Read more

MDxHealth (R) : MDxHealth Notice of Interim Results 2018

Read more

argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody

Read more

SelectMDx Cost-effective in Four European Countries

Read more

argenx receives feedback from Japan's PMDA on Phase 3 clinical trial

Read more

Services

Read more

Gilead and Galapagos announce filgotinib meets primary and all key secondary endpoints in first phase 3 study in rheumatoid arthritis

Read more

Mithra announces further details regarding contract gedeon richter

Read more

MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner

Read more

Mithra Finalizes Contract for the Commercialization of Estelle® with South Korean Women's Health Leader Hyundai Pharm

Read more

Mithra Signs Exclusive License And Supply Agreement For The Commercialization Of Myring™ In Chile With Laboratorio Pasteur

Read more

Daily newsflash - 03/10/2018

Read more

argenx awarded €2.6 million VLAIO grant to explore new applications of ABDEG technology

Read more

Shareholder Transparency Declaration MDxHealth

Read more

Galapagos reports initiation of PINTA Phase 2 trial with GLPG1205 in patients with Idiopathic Pulmonary Fibrosis (IPF)

Read more

Oxurion and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatment of dry AMD

Read more

MDxHealth (R): SelectMDx improves prostate biopsy decision-making in urology practices

Read more

Mithra Announces the Completion of its Lead Clinical Phase III Programme for Estelle®

Read more

Mithra signs exclusive license and supply agreement for vaginal contraceptive ring in Australia and New Zealand

Read more

Mithra reduces environmental impact of CDMO facility in Belgium with the installation of 1800 solar panels

Read more

MDxHealth Announces Approval for SelectMDx for Prostate Cancer by New York State

Read more

Mithra Announces Positive Results of Ovarian Function Sub-Study which Strengthens Estelle® Contraceptive Efficacy Profile

Read more

Mithra announces Myring™ update

Read more

Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary Fibrosis (IPF)

Read more

Invitation: flanders.health workshop & Life-on-chip event

Read more

Networking - 04/04/2019, Brussels

Read more

Mithra announces complex therapeutics update

Read more

Mithra Announces Attendance at the 37th Annual J.P. Morgan Healthcare Conference

Read more

Biocartis Group NV: Biocartis and Nichirei Bioscience Announce Commercialization Collaboration for Japanese Market

Read more

MDxHealth (R): MDxHealth Provides Business Update

Read more

Invitation: Life-on-chip event

Read more

Mithra wins BelMid Company of the Year 2018

Read more

argenx announces closing of exclusive global collaboration and license agreement for cusatuzumab (ARGX-110) with Janssen

Read more

Mithra announces 2019 financial calendar

Read more

Daily Newsflash - 22/01/2019

Read more

SelectMDx Outperforms Prostate Health Index (phi) Blood Test for Detecting High-Grade Prostate Cancer

Read more

Mithra Strengthens Management Team With Key Appointments

Read more

Sequana Medical announces the Coverage of the Base Offering of Its Initial Public Offering on Euronext Brussels

Read more

Sequana Medical raises €27.5 million in successful Initial Public Offering

Read more

Mithra Signs Exclusive License and Supply Agreement for Commercialization of Myring™ in the Middle East

Read more

Mithra Successfully Produces its First Commercial Batch of Myring™ for Europe

Read more

MDxHealth (R): MDxHealth Signs Partnership with LifeLabs to Make SelectMDx available in Canada

Read more

MDxHealth Announces Presentation of Positive Data for SelectMDx and ConfirmMDx in Prostate Cancer Diagnosis

Read more

Sequana Medical NV: DISCLOSURE OF OUTSTANDING VOTING SECURITIES

Read more

MDxHealth Appoints Michael K. McGarrity as CEO

Read more

Mithra Announces New Polymer Technology Development for a Leading Veterinarian Company

Read more

argenx to receive first clinical milestone payment for product candidate developed under option agreement with AbbVie

Read more

MDxHealth Announces Positive Data from Pan-European Clinical Validation Study of SelectMDx

Read more

Mithra Demonstrates Further Estetrol’s Unique Profile at the Annual Meeting of the Endocrine Society

Read more

Genkyotex Reverse Stock Split Takes Effect

Read more

Mithra receives Orphan Drug Designation from FDA for E4 in neonatal encephalopathy treatment

Read more

Mithra wins essenscia Innovation Award 2019 for its new generation contraceptive pill, Estelle®

Read more

Mithra announces new agreement with GSP for development of an additional injectable

Read more

Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients

Read more

Mithra Signs License and Supply Agreement for Commercialization of Myring™ in Latin and South America

Read more

ActoBio Therapeutics™’ CTO Lothar Steidler Elected VIB Alumni Awardee 2019

Read more

eTheRNA immunotherapies opens new research base in Ghent

Read more

SYMPOSIUM: Cellular Therapies in Oncology and Beyond: from Drug Development to Clinical Applications

Read more

eTheRNA: Appointment of Chief Financial Officer

Read more

ActoBio Therapeutics™ Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 Diabetes

Read more

Mithra CDMO Strengthens its Management Team and Accelerates Key R&D Programs

Read more

Single-Use Event 2019: Challenges and opportunities in bioprocessing and biopharma

Read more

Towards high-quality Cell Therapy

Read more

ESPERITE's shareholders approved the external financing of up to EUR 13 million

Read more

Thank you for attending the latest flanders.bio - Roche Diagnostics Partner Day

Read more

Daily Newsflash- 19/06/17

Read more

Daily Newsflash- 20/09/2017

Read more

Daily newsflash - 29/06/2018

Read more

Weekly newsflash - 26/07/2018

Read more

Next-Generation Protein Analysis and Detection (3rd edition)

Read more

Lessons in Herding Cats: Business Development for Life Science Companies

Read more

Revolutionizing Next-Generation Sequencing (3rd edition)

Read more